Sanofi and AZ’s RSV Antibody Gets EU Thumbs Up But Pfizer Rival Hot On Heels

 
• By Ayisha Sharma

Nirsevimab is set to become the second RSV prophylactic on the market for infants and offers several advantages over its first-to-market competition, but Pfizer’s vaccine rival is fast approaching.  

Sport. Runner. Side view of a jogger legs with the power in the veins isolated on black. Fire and energy.
The RSV R&D Space Is Dominated By Big Pharma Contenders • Source: Shutterstock

More from Business

More from Scrip